Abstract Submission - General Guidelines and Regulations

Call for Abstracts and Abstract Submission Guidelines
The EAACI Scientific Programme Committee and the Local Organising Committee welcome the submission of original contributions for abstracts at the EAACI Hybrid Congress 2021.

DEADLINE: MONDAY 1 FEBRUARY 2021 at 23:59 CET

EAACI does not charge any fee for regular abstract submission. Abstracts can only be submitted in the online platform on the EAACI website. Abstracts submitted via email, post or fax will not be accepted.

1. General information

1.1 Instructions to authors
Carefully read the guidelines below before submitting your abstract:
Abstracts not adhering to EAACI Abstract Submission – General Guidelines and Regulations will be rejected. The final decision about acceptance of an abstract will be taken by the EAACI Scientific Programme Committee. EAACI does not communicate, nor enter into correspondence on the reason for acceptance or rejection of an abstract.

Upon submission, a confirmation email will be sent to the submitters email address. If you do not receive the confirmation e-mail, please do not submit the abstract again. Instead, please contact the Scientific Secretariat abstract@eaaci.org for advice.

1.2 Submission categories
Abstracts can be submitted in the different topics shown on the EAACI website.

1.3 Declaration of conflict of interest
EAACI is committed to ensuring the integrity of scientific, educational, and research programmes. Abstract submission requires disclosure of any financial or other interest that might be construed as resulting in an actual, potential, or apparent conflict. The submitter is responsible for obtaining disclosure information from all co-authors, to be entered in the author section of the submission page.

2. Submission guidelines

2.1 Technical requirements

2.1.1 Personal Page
When entering the abstract submission system for the first time, you will be asked to create a profile. Through your account you will be able to access your personal page to submit one or several abstracts. You can edit your abstracts until the submission deadline on Monday 1 February 2021, 23:59 CET.

2.1.2 Abstract language and length
Abstracts and presentations must be written in English. The maximum length allowed for an abstract is 2500 characters (approximately 350 words) including blank spaces. The abstract title, the author(s) or names of institutions are not included in the count of 2500 characters.
2.1.3 Tables and Figures
If appropriate one table and/or one figure (charts, diagrams and statistical overviews uploaded as a picture) are allowed. Please do not upload any kind of patient pictures.

Accepted file formats are .jpg / .png / .gif. Your file should not exceed 3000 KB (3MB).

2.1.4 Abstract structure and content
In order to make the abstract as informative as possible, we require a brief statement of the purpose of the study and/or the underlying hypotheses (background), the method used, the results observed, and the conclusions based upon the results. Abstracts without results will be rejected. It is inadequate to state “The results will be discussed” or “The data will be presented”.

2.1.5 Tradenames
Trade names are not allowed as well as copyright and trademark symbols. Non-properitary (generic) names of drugs, written in lower case, are required the first time a drug is mentioned in the text. References, credits or the authors’ academic degrees or grant support are not to be included in the abstract. Standard abbreviations may be employed in the text. Place special or unusual abbreviations in parentheses after the full wording at the first time it appears in the body of the text. Company names and logos are not allowed in the title but can be named in the authors’ affiliation.

2.1.6 Consent for publication of individual patient data - applies to abstracts with identifiable patient data
For the publication of an abstract that contains identifiable information about patients, it is necessary that patients have given consent for the research to be published. For all abstracts that include identifiable patient details (e.g. gender, age, illness, location) or images, written informed consent for the publication of these must be obtained from the patient (or their parent or legal guardian).

It is the author’s responsibility to obtain written informed consent for publication of clinical details and/or clinical images from the patient/parent/guardian/relative of the patient. A respective statement needs to be included in the abstract text.

2.1.7 Duplication of publications
Unpublished abstracts that have been presented at a different scientific meeting within a 12 months period prior to EAACI Hybrid Congress 2021, provided they contain updated/additional data, can be submitted and will be considered for presentation. Abstracts submitted for publication or to a scientific meeting, but are pending acceptance, can be submitted without restrictions. However, once the abstract has been accepted by EAACI it is automatically subject to the EAACI embargo policy (2.3.6).

2.2 Abstract presentation
2.2.1 Presentation formats and abstract topics
Accepted abstracts selected by expert reviewers will be presented in any of the following sessions: Oral Abstract Sessions (OAS), Poster Discussion Session (PDS), E-Poster Session and Poster Display Only.

It is the author’s responsibility to submit a correct abstract. Any errors in spelling, grammar or scientific fact will be reproduced as typed by the author as no editing or proofreading will be done by EAACI. Please note that each year a number of abstracts are rejected because of poor English or because they contain no or incomplete data.

For clinical studies, clinical trials or translational research abstract submissions, the presenting author can be any of the listed authors, but without affiliations to industry.

For basic research abstract submissions, the presenting author can be any of the listed authors.
2.2.2 Oral Abstract Session
The Oral Abstract Sessions (OAS) consist of oral presentations followed by discussion. As presenter you are required to prepare a MS PowerPoint presentation featuring the main findings of your work.

2.2.3 Poster Discussion Session
The Poster Discussion Session (PDS) will allow for presentation of your work in electronic format. Each Poster Discussion Session contains 12-18 posters and runs for 90 minutes. Each abstract presenter will have the opportunity to summarise their main findings in 5 minutes max (depending on the number of abstracts per session.)

2.2.4 E-Poster Session
The e-posters can be found in the e-poster section of the digital platform as a digital poster with a 4 minutes voice-over. Recorded poster presentations will allow for presentation of your work in electronic format. Your PDF will be made available on the digital congress platform, allowing the participants to view it during the whole event, and uploaded on the EAACI content platform after the event, given that the author gave consent to it.

Each abstract presenter will have the opportunity to summarise their main findings. Prior to the digital congress, you are required to upload the poster and record your voice-over in the designated system provided to you. An email with detailed information and the link to upload your poster will be sent to the presenting author in due course."

2.2.5 Poster Display Only
The Poster Display Only will be available only on the congress digital platform and will not be included in the Allergy Journal.

2.2.5 Poster Size and Format
All posters will be presented in landscape format 16:9 and have only one slide with voice-over. Detailed instructions for the preparation of visual presentations and posters will be made available on the EAACI website in May.

2.3 Abstract instructions
2.3.1 Notification of acceptance
Notifications of acceptance or rejection of the abstracts will be sent to the presenting author of the abstract by end of March 2021.

The submitting author will receive the confirmation email stating that the abstract has been submitted successfully. All further communication including notification letter will be ONLY with the presenting author that has been indicated during the abstract submission.

With the notification of acceptance, abstract presenters will be informed about the format. EAACI cannot guarantee that presenting authors who do not upload their presentation/poster of their abstract on the digital platform will be accepted for abstract presentations at future congresses. These “no-shows” are refused for publication on the Allergy Journal and the EAACI content platform.

The presenting author must be registered using the same email address which was used for the abstract submission. This is to ensure that the abstract and registration can be matched. If the presenting author is not registered by 31 May 2021 and/or the email addresses used do not match, the abstract will not be published in the congress programme or in the Allergy Journal.
Your abstract will only be published if the abstract is accepted, the poster is uploaded, and the presenting author is registered using the same email address used for abstract submission.

2.3.2 Registration
The presenting author of an abstract must register for the congress (digital congress or hybrid congress). Until 31 March 2021 the presenting author is offered a special extended “early fee”. The registration fee may be refunded if the abstract is rejected. Please note that some countries require a visa to visit Poland.

2.3.3 Publication of abstracts
Accepted abstracts will be published in the online programme, EAACI website and EAACI content platform during the Congress. Publication of the abstracts as a supplement in the Allergy Journal will be done after the congress. Please note that your abstract will only be published in the Allergy journal if the abstract is accepted, the poster is uploaded, and the presenting author is registered using the same email address used for abstract submission. In order to have your abstract published on the website you need to be registered for the congress by 31 May 2021 (Digital registration or for the Hybrid Congress). Kindly note that all abstracts selected for Poster Display Only (former on-site poster display) will NOT be published on the EAACI content platform nor in the Allergy Journal.

2.3.4 No-show policy
Submission of an abstract constitutes a formal commitment by the author(s) to present the work if accepted. If a presenting author of an accepted abstract does not upload his/her poster until the deadline, he/she risks jeopardizing future acceptance at other EAACI Congresses and Events, if not justified (withdrawn). These abstracts will be excluded from publication in the Allergy Journal and on the EAACI content platform.

2.3.5 Withdrawal of an abstract
If you need to withdraw your abstract, a written statement listing the reasons for this decision must be sent to the EAACI Scientific Secretariat no later than 12 April 2021 (abstract@eaaci.org). Withdrawals after this date cannot be accepted.

2.3.6 Abstract Embargo
Accepted abstracts are made available to the public on the EAACI content platform, EAACI website and on the EAACI App on the first day of the EAACI Congress at 00:01 CEST. Hence, the embargo is lifted at 00:01hrs CEST on the starting day of the EAACI Congress and can be reported from that time onwards. All presented abstracts (except “Poster Display Only”) will also be published in the Allergy Journal after the EAACI Congress. EAACI and Wiley hold copyright of all accepted abstracts for the EAACI Congress and therefore abstracts cannot be made public prior to official release. Copyright is only lifted if the abstract is not accepted for publication in the Allergy Journal after the EAACI Congress. Violation of the embargo may result in the abstract being withdrawn from the congress and/or other measures deemed appropriate. It is not considered a violation of this policy if an abstract or information thereof is presented elsewhere or is part of a manuscript that has already been submitted, if acceptance is still pending at the time of the regular abstract submission deadline. Upon abstract acceptance for the EAACI Hybrid Congress 2021, withdrawal from other publications is mandatory.

2.3.7 Copyright
By submitting your abstract to the EAACI Hybrid 2021 you are agreeing to the transfer of the copyright to EAACI/Wiley.
EAACI copyright is only lifted if the abstract is not accepted for publication in the Allergy Journal after the congress.

The submission of abstracts accepted for EAACI Hybrid Congress 2021 and published in the Allergy Journal, requires the permission of EAACI/Wiley as copyright holder. Requests must be done via the Wiley online system.

Commercial data mining of abstracts published in the Allergy Journal requires the permission of EAACI/Wiley and approval must be sought before inception of the project via the Wiley online system.

2.3.8 Data Privacy

By certifying that you have read these submission rules, you also confirm having received the prior approval from the co-authors to provide their data to the EAACI Hybrid Congress 2021.

The information collected in this call for abstract submission is subject to data processing to proceed with the elaboration of the Scientific Programme during the EAACI Hybrid Congress 2021.

Provision of personal data is a statutory requirement to list the authors who have contributed to research submitted. Authors not listed in the submission will not be acknowledged in the abstract, if accepted for publication on the EAACI content platform or the Allergy Journal or presentation at the Congress.

Your personal data will be shared with EAACI, KIT, the EAACI Committees, and abstract reviewers involved in the abstract selection for the EAACI Hybrid Congress 2021. Transfer of personal data to contactors as well as EAACI related scientific organisations may occur for production, promotion and dissemination of congress content.

In accordance with the chapter 3 of the European Regulation 2016/679 with regards to data protection, you have the right to request EAACI access, rectification or erasure of your personal data, restriction or object to processing as well as the right to data portability. This is one thru withdrawal of the abstract according to the terms and conditions of withdrawal. For such, please contact (together with a proof of identity):

Data Privacy
European Academy of Allergy and Clinical Immunology (EAACI)
Attn: Charalampos Kostaras / Hagenholzstrasse 111 / CH-8050 Zurich / Or by email to: gdpr@eaaci.org

2.3.9 Abstract Review

All abstracts will be blinded for review by a minimum of 3 members of the abstract review committee. All the reviewers have been selected by the Scientific Programme Committee to review abstracts in their category that best fits their expertise. EAACI aims for good quality of science without compromising scientific integrity.

The abstract reviewers are required to identify abstracts pertaining to commercial promotion of a proprietary product or data originating from the same study across several abstracts in order to notify the Scientific Programme Committee for further action.

Please note that the final decisions regarding acceptance of the submitted abstract will be made by the Scientific Programme Committee. No rescheduling or changes by the submitters will be possible once the abstract deadline is closed.
Contact
For any assistance for the submission of the abstract please contact the Scientific Secretariat at:
abstract@eaaci.org

Deadlines are subject to change. Date: 16 November 2020